Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications

Darya Mırdamad; Bahar Kural

Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications

Abstract

Human papillomavirus (HPV) is the most important factor in the development of oropharyngeal, anogenital malignant and premalignant warts and cervix cancer in women. Transmission can occur through trauma to the skin or mucosa and with sexual intercourse. HPV infections can be prevented by vaccination and are included in vaccination programs in most countries as primary protection in adolescents. The countries that started HPV vaccination at the earliest in the world were the United States of America (USA), Switzerland, France and Monaco in 2006. Turkmenistan has the highest vaccination rate, which started the vaccination program in 2016. In this analysis Eswatini have the highest rates in cervix cancers and need to start vaccinations . Studies for adolescent health programs are continuing to initiate adolescent vaccination in Türkiye. In this review, the administration rates of HPV vaccines and the changes in HPV-related cancer rates by country in the world are examined.

Keywords

References

Al-Awadhi, R., Chehadeh, W., Jaragh, M., Al-Shaheen, A., Sharma, P., & Kapila, K. (2013). Distribution of human papillomavirus among women with abnormal cervical cytology in Kuwait. Diagnostic Cytopathology, 41(2). https://doi.org/10.1002/dc.21778
Alene, T., Atnafu, A., Mekonnen, Z. A., & Minyihun, A. (2020). Acceptance of human papillomavirus vaccination and associated factors among parents of daughters in gondar town, northwest Ethiopia. Cancer Management and Research, 12. https://doi.org/10.2147/CMAR.S275038
Arbyn, M., Simoens, C., Van Damme, P., Scharpantgen, A., Meijer, C. J. L. M., & Beutels, P. (2010). Introduction of human papillomavirus vaccination in Belgium, Luxembourg and The Netherlands. Gynecologic and Obstetric Investigation, 70(4). https://doi.org/10.1159/000314010
Athanasiou, A., Bowden, S., Paraskevaidi, M., Fotopoulou, C., Martin-Hirsch, P., Paraskevaidis, E., & Kyrgiou, M. (2020). HPV vaccination and cancer prevention. In Best Practice and Research: Clinical Obstetrics and Gynaecology (Vol. 65). https://doi.org/10.1016/j.bpobgyn.2020.02.009
Audisio, R. A., Icardi, G., Isidori, A. M., Liverani, C. A., Lombardi, A., Mariani, L., Mennini, F. S., Mitchell, D. A., Peracino, A., Pecorelli, S., Rezza, G., Signorelli, C., Rosati, G. V., & Zuccotti, G. V. (2016). Public health value of universal HPV vaccination. In Critical Reviews in Oncology/Hematology (Vol. 97). https://doi.org/10.1016/j.critrevonc.2015.07.015
Blakely, T., Kvizhinadze, G., Karvonen, T., Pearson, A. L., Smith, M., & Wilson, N. (2014). Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine, 32(22). https://doi.org/10.1016/j.vaccine.2014.02.071
Boiron, L., Joura, E., Largeron, N., Prager, B., & Uhart, M. (2016). Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infectious Diseases, 16(1). https://doi.org/10.1186/s12879-016-1483-5
Brotherton, J. M. L., Winch, K. L., Bicknell, L., Chappell, G., & Saville, M. (2017). HPV vaccine coverage is increasing in Australia. Medical Journal of Australia, 206(6). https://doi.org/10.5694/MJA16.00958

Carlton, J. G., Marembo, J., Manangazira, P., Rupfutse, M., Shearley, A., Makwabarara, E., Hidle, A., & Loharikar, A. (2022). Nationwide introduction of HPV vaccine in Zimbabwe 2018–2019: Experiences with multiple cohort vaccination delivery. PLOS Global Public Health, 2(4). https://doi.org/10.1371/journal.pgph.0000101
Centers for Disease Control and Prevention. (2023). HPV vaccine information for clinicians. U.S. Department of Health & Human Services. https://www.cdc.gov/hpv/clinicians/index.html
Chung, M., York, B. R., & Michaud, D. S. (2019). Oral Health and Cancer. In Current Oral Health Reports (Vol. 6, Issue 2). https://doi.org/10.1007/s40496-019-0213-7
Clark, S. J., Cowan, A. E., Filipp, S. L., Fisher, A. M., & Stokley, S. (2016). Parent HPV vaccine perspectives and the likelihood of HPV vaccination of adolescent males. Human Vaccines and Immunotherapeutics, 12(1). https://doi.org/10.1080/21645515.2015.1073426
De Groot, A. S., Tounkara, K., Rochas, M., Beseme, S., Yekta, S., Diallo, F. S., Tracy, J. K., Teguete, I., & Koita, O. A. (2017). Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PLoS ONE, 12(2). https://doi.org/10.1371/journal.pone.0171631
Dorji, Tandin, Tshomo, U., Phuntsho, S., Tamang, T. D., Tshokey, T., Baussano, I., Franceschi, S., & Clifford, G. (2015). Introduction of a National HPV vaccination program into Bhutan. Vaccine, 33(31). https://doi.org/10.1016/j.vaccine.2015.05.078
Dorji, Thinley, Tshomo, U., Gyamtsho, S., Tamang, S. T., Wangmo, S., & Pongpirul, K. (2022). Gender-neutral HPV elimination, cervical cancer screening, and treatment: Experience from Bhutan. In International Journal of Gynecology and Obstetrics (Vol. 156, Issue 3). https://doi.org/10.1002/ijgo.13728
Fagot, J. P., Boutrelle, A., Ricordeau, P., Weill, A., & Allemand, H. (2011). HPV vaccination in France: Uptake, costs and issues for the National Health Insurance. Vaccine, 29(19). https://doi.org/10.1016/j.vaccine.2011.02.064
Fisher, W. A., Laniado, H., Shoval, H., Hakim, M., & Bornstein, J. (2013). Barriers to Human Papillomavirus Vaccine Acceptability in Israel. In Vaccine (Vol. 31, Issue SUPPL.8). https://doi.org/10.1016/j.vaccine.2013.06.107
Gordis, L. (2014). Prevention and control of disease (Chap. 8). In Epidemiology (6th ed.). Elsevier
Garland, S. M., Skinner, S. R., & Brotherton, J. M. L. (2011). Adolescent and young adult HPV vaccination in Australia: Achievements and challenges. In Preventive Medicine (Vol. 53, Issue SUPPL. 1). https://doi.org/10.1016/j.ypmed.2011.08.015
Ginindza, T. G., Forestier, M., & Almonte, M. (2022). Cervical cancer screening by visual inspection and HPV testing in Eswatini. Preventive Medicine, 161. https://doi.org/10.1016/j.ypmed.2022.107144
Gomes, J. M., Silva, B. M., de Sousa Santos, E. F., Kelly, P. J., de Souza Costa, A., Takiuti, A. D., de Abreu, L. C., Júnior, J. M. S., Baracat, E. C., Cristina, I., & Sorpreso, E. (2020). Human Papillomavirus (HPV) and the quadrivalent HPV vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance. PLoS ONE, 15(11 November). https://doi.org/10.1371/journal.pone.0241674
Gultekin, M., Karaca, M. Z., Kucukyildiz, I., Dundar, S., Keskinkilic, B., & Turkyilmaz, M. (2019). Mega Hpv laboratories for cervical cancer control: Challenges and recommendations from a case study of Turkey. Papillomavirus Research, 7. https://doi.org/10.1016/j.pvr.2019.03.002
Hamkar, R., Shoja, Z., Ghavami, N., Heydari, N., Farahmand, M., & Jalilvand, S. (2018). Type-Specific Human Papillomavirus Prevalence in Iranian Women with Normal Cervical Cytology: The Impact of Current HPV Vaccines. Intervirology, 60(4). https://doi.org/10.1159/000485898
Jacot-Guillarmod, M., Pasquier, J., Greub, G., Bongiovanni, M., Achtari, C., & Sahli, R. (2017). Impact of HPV vaccination with Gardasil® in Switzerland. BMC Infectious Diseases, 17(1). https://doi.org/10.1186/s12879-017-2867-x
Kjær, S. K., Breugelmans, G., Munk, C., Junge, J., Watson, M., & Iftner, T. (2008). Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. International Journal of Cancer, 123(8). https://doi.org/10.1002/ijc.23712
Lefèvre, H., Schrimpf, C., Moro, M. R., & Lachal, J. (2018). HPV vaccination rate in French adolescent girls: An example of vaccine distrust. Archives of Disease in Childhood, 103(8). https://doi.org/10.1136/archdischild-2017-313887
Lynge, E., Thamsborg, L., Larsen, L. G., Christensen, J., Johansen, T., Hariri, J., Christiansen, S., Rygaard, C., & Andersen, B. (2020). Prevalence of high-risk human papillomavirus after HPV-vaccination in Denmark. International Journal of Cancer, 147(12). https://doi.org/10.1002/ijc.33157
Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016). Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics, 137(3). https://doi.org/10.1542/peds.2015-1968
Marlow, L. A.V. (2011). HPV vaccination among ethnic minorities in the UK: Knowledge, acceptability and attitudes. British Journal of Cancer, 105(4). https://doi.org/10.1038/bjc.2011.272
Marlow, Laura A.V., Zimet, G. D., McCaffery, K. J., Ostini, R., & Waller, J. (2013). Knowledge of human papillomavirus (HPV) and HPV vaccination: An international comparison. Vaccine, 31(5). https://doi.org/10.1016/j.vaccine.2012.11.083
Mphuru, A., Li, A. J., Kyesi, F., Mwengee, W., Mazige, F., Nshunju, R., Shayo, B., Giattas, M. R., Loharikar, A., & Lyimo, D. (2022). National introduction of human papillomavirus (HPV) vaccine in Tanzania: Programmatic decision-making and implementation. Vaccine, 40. https://doi.org/10.1016/j.vaccine.2021.04.025
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003). Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer. New England Journal of Medicine, 348(6). https://doi.org/10.1056/nejmoa021641
Osmani, V., & Klug, S. J. (2021). HPV vaccination and the prevention of genital warts and precancerous lesions—current evidence and evaluation. In Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (Vol. 64, Issue 5). https://doi.org/10.1007/s00103-021-03316-x
Patel, C., Brotherton, J. M. L., Pillsbury, A., Jayasinghe, S., Donovan, B., Macartney, K., & Marshall, H. (2018). The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: What additional disease burden will a nonavalent vaccine prevent? In Eurosurveillance (Vol. 23, Issue 41). https://doi.org/10.2807/1560-7917.ES.2018.23.41.1700737
Paul, K. T. (2016). “Saving lives”: Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria. Social Science and Medicine, 153. https://doi.org/10.1016/j.socscimed.2016.02.006
Petca, A., Borislavschi, A., Zvanca, M., Petca, R.-C., Sandru, F., & Dumitrascu, M. (2020). Non-sexual HPV transmission and role of vaccination for a better future (Review). Experimental and Therapeutic Medicine, 20(6). https://doi.org/10.3892/etm.2020.9316
Petrosky, E., Bocchini, J. A., Hariri, S., Chesson, H., Curtis, C. R., Saraiya, M., Unger, E. R., Markowitz, L. E., & Centers for Disease Control and Prevention (CDC). (2015). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR. Morbidity and Mortality Weekly Report, 64(11), 300–304.
Pista, A., de Oliveira, C. F., Lopes, C., Cunha, M. J., Tavares, A., Dias, M., Rocha, E., da Conceição Telhado, M., Afonso, A., Loureiro, M., Horgan, C., Marques, I., Cortes, E., Alegra, S., do Carmo Serra, M., Lima, J., Afonso, E., Ladeira, A. P., Gonçalves, L., … Santos, S. (2017). Potential impact of nonavalent HPV vaccine in the prevention of high-grade cervical lesions and cervical cancer in Portugal. International Journal of Gynecology and Obstetrics, 139(1). https://doi.org/10.1002/ijgo.12243
Riesen, M., Garcia, V., Low, N., & Althaus, C. L. (2017). Modeling the consequences of regional heterogeneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland. Vaccine, 35(52). https://doi.org/10.1016/j.vaccine.2017.10.103
Riesen, M., Konstantinoudis, G., Lang, P., Low, N., Hatz, C., Maeusezahl, M., Spaar, A., Bühlmann, M., Spycher, B. D., & Althaus, C. L. (2018). Exploring variation in human papillomavirus vaccination uptake in Switzerland: A multilevel spatial analysis of a national vaccination coverage survey. In BMJ Open (Vol. 8, Issue 5). https://doi.org/10.1136/bmjopen-2017-021006
Rondy, M., van Lier, A., van de Kassteele, J., Rust, L., & de Melker, H. (2010). Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine, 28(9). https://doi.org/10.1016/j.vaccine.2009.12.042
Sargazi, N., Takian, A., Yaseri, M., Daroudi, R., Ghanbari Motlagh, A., Nahvijou, A., & Zendehdel, K. (2021). Mothers’ preferences and willingness-to-pay for human papillomavirus vaccines in Iran: A discrete choice experiment study. Preventive Medicine Reports, 23. https://doi.org/10.1016/j.pmedr.2021.101438
Schülein, S., Taylor, K. J., König, J., Claus, M., Blettner, M., & Klug, S. J. (2016). Factors influencing uptake of HPV vaccination among girls in Germany. BMC Public Health, 16(1). https://doi.org/10.1186/s12889-016-3663-z
Shahbari, N. A. E., Gesser-Edelsburg, A., Davidovitch, N., Brammli-Greenberg, S., Grifat, R., & Mesch, G. S. (2021). Factors associated with seasonal influenza and HPV vaccination uptake among different ethnic groups in Arab and Jewish society in Israel. International Journal for Equity in Health, 20(1). https://doi.org/10.1186/s12939-021-01523-1
Shahbari, N. A. E., Gesser-Edelsburg, A., & Mesch, G. S. (2019). Case of paradoxical cultural sensitivity: Mixed method study of web-based health informational materials about the human papillomavirus vaccine in Israel. Journal of Medical Internet Research, 21(5). https://doi.org/10.2196/13373
Shaltout, M. F., Sallam, H. N., AbouSeeda, M., Moiety, F., Hemeda, H., Ibrahim, A., Sherbini, M. E. L., Rady, H., Gopala, K., & DeAntonio, R. (2014). Prevalence and type distribution of human papillomavirus among women older than 18 years in Egypt: A multicenter, observational study. International Journal of Infectious Diseases, 29. https://doi.org/10.1016/j.ijid.2014.07.029
Shapiro, G. K., Guichon, J., & Kelaher, M. (2017). Canadian school-based HPV vaccine programs and policy considerations. Vaccine, 35(42). https://doi.org/10.1016/j.vaccine.2017.07.079
Sharma, S., Deep, A., & Sharma, A. K. (2020). Current Treatment for Cervical Cancer: An Update. Anti-Cancer Agents in Medicinal Chemistry, 20(15). https://doi.org/10.2174/1871520620666200224093301
Simoens, C., Sabbe, M., Van Damme, P., Beutels, P., & Arbyn, M. (2009). Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin, 14(46). https://doi.org/10.2807/ese.14.46.19407-en
Stanley, M. (2014). HPV vaccination in boys and men. Human Vaccines & Immunotherapeutics, 10(7). https://doi.org/10.4161/hv.29137
Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Cummins, E., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., & Garland, S. M. (2012). Fall in human papillomavirus prevalence following a national vaccination program. Journal of Infectious Diseases, 206(11). https://doi.org/10.1093/infdis/jis590
Tanaka, Y., Ueda, Y., Egawa-Takata, T., Yagi, A., Yoshino, K., & Kimura, T. (2016). Outcomes for girls without HPV vaccination in Japan. In The Lancet Oncology (Vol. 17, Issue 7). https://doi.org/10.1016/S1470-2045(16)00147-9
Tay, S. K., Lee, B. W., Sohn, W. Y., Lee, I. H., Mathur, G., Sanicas, M., & Van Kriekinge, G. (2018). Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Singapore Medical Journal, 59(7). https://doi.org/10.11622/smedj.2017085
The Catalan Institute of Oncology & International Agency for Research on Cancer. (2023). HPV Information Centre. https://hpvcentre.net
Thinn, M. M., Aung, S., Aung, A., & Tun, N. M. (2023). Current Status of Cervical Cancer Prevention and Screening in Myanmar. In South Asian Journal of Cancer (Vol. 12, Issue 1). https://doi.org/10.1055/s-0043-1764212
Trétarre, B., Dantony, E., Coureau, G., Defossez, G., Guizard, A. V., Delafosse, P., Daubisse, L., Velten, M., Karima Hammas, Barra, S., Lapotre, B., Plouvier, S., d’Almeida, T., Molinié, F., & Woronoff, A. S. (2023). Trends in incidence of invasive vaginal cancer in France from 1990 to 2018 and survival of recently diagnosed women – A population-based study. European Journal of Obstetrics and Gynecology and Reproductive Biology, 283. https://doi.org/10.1016/j.ejogrb.2023.02.003
Walwyn, L., Janusz, C. B., Clark, A. D., Prieto, E., Waight, E., & Largaespada, N. (2015). Cost-effectiveness of HPV vaccination in Belize. Vaccine, 33(S1). https://doi.org/10.1016/j.vaccine.2014.12.042
World Health Organization. (2022). Cervical cancer: Prevention and control. https://www.who.int/news‑room/fact‑sheets/detail/cervical‑cancer
World Health Organization. (2024). Human papillomavirus (HPV) vaccination coverage. https://www.who.int/news-room/fact- sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
Yaghoubi, M., Nojomi, M., Vaezi, A., Erfani, V., Mahmoudi, S., Ezoji, K., Zahraei, S. M., Chaudhri, I., & Moradi-Lakeh, M. (2018). Cost-Effectiveness Analysis of the Introduction of HPV Vaccination of 9-Year-Old-Girls in Iran. Value in Health Regional Issues, 15. https://doi.org/10.1016/j.vhri.2018.03.001
Zhu, Y., Wu, C. F., Giuliano, A. R., Fernandez, M. E., Ortiz, A. P., Cazaban, C. G., Li, R., Deshmukh, A. A., & Sonawane, K. (2022). Tdap-HPV vaccination bundling in the USA: Trends, predictors, and implications for vaccine series completion. Preventive Medicine, 164. https://doi.org/10.1016/j.ypmed.2022.107218
Zhuang, Q. Y., Wong, R. X., Chen, W. M. D., & Guo, X. X. (2016). Knowledge, attitudes and practices regarding human papillomavirus vaccination among young women attending a tertiary institution in Singapore. Singapore Medical Journal, 57(6). https://doi.org/10.11622/smedj.2016108

Details

Primary Language

English

Subjects

Community Child Health, Public Health (Other)

Journal Section

Review Article

Authors

Darya Mırdamad ^*
0009-0005-9424-4683
Türkiye

Bahar Kural
Türkiye

Publication Date

January 28, 2026

Submission Date

July 15, 2025

Acceptance Date

October 9, 2025

Published in Issue

Year 2026 Volume: 2 Number: 1

IZ

https://izlik.org/JA24PT38KN

Cite

RIS / Bibtex

APA

Mırdamad, D., & Kural, B. (2026). Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications. Journal of Child Development and Education, 2(1), 43-51. https://izlik.org/JA24PT38KN

AMA

1.Mırdamad D, Kural B. Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications. JOCDE. 2026;2(1):43-51. https://izlik.org/JA24PT38KN

Chicago

Mırdamad, Darya, and Bahar Kural. 2026. “Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications”. Journal of Child Development and Education 2 (1): 43-51. https://izlik.org/JA24PT38KN.

EndNote

Mırdamad D, Kural B (January 1, 2026) Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications. Journal of Child Development and Education 2 1 43–51.

IEEE

[1]D. Mırdamad and B. Kural, “Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications”, JOCDE, vol. 2, no. 1, pp. 43–51, Jan. 2026, [Online]. Available: https://izlik.org/JA24PT38KN

ISNAD

Mırdamad, Darya - Kural, Bahar. “Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications”. Journal of Child Development and Education 2/1 (January 1, 2026): 43-51. https://izlik.org/JA24PT38KN.

JAMA

1.Mırdamad D, Kural B. Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications. JOCDE. 2026;2:43–51.

MLA

Mırdamad, Darya, and Bahar Kural. “Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications”. Journal of Child Development and Education, vol. 2, no. 1, Jan. 2026, pp. 43-51, https://izlik.org/JA24PT38KN.

Vancouver

1.Darya Mırdamad, Bahar Kural. Protecting Adolescents Against HPV: International Vaccination Strategies and Public Health Implications. JOCDE [Internet]. 2026 Jan. 1;2(1):43-51. Available from: https://izlik.org/JA24PT38KN